文档介绍：The Need for Biomarkers in Diagnosis and Prognosis of Drug-Induced Liver Disease: Does Metabolomics Have Any Role ? 生物标志物在药物诱导的肝脏疾病的诊断和预断中的需要:代谢组学是否有何作用? 1. Introduction Liver injury due to both prescription and over-the-counter drugs is a growing public health problem. Although drug-induced liver injury (DILI) is a rare cause of acute liver injury in clinical practice, it is the leading cause of acute liver failure (ALF) in the US and most of Europe. 处方药和非处方药导致的肝损伤是一个日益严重的公共卫生问题。尽管药物诱导的肝损伤( DILI )在临床实践中是急性肝损伤的罕见原因,但它是美国和大多数欧洲的急性肝衰竭( ALF )的主要原因 1. Introduction Despite the extensive safety tests performed in the process of getting a drug to market, DILI remains enigmatic and cannot be predicted in preclinical and clinical trials. Even though different ic variants and biomarkers have been associated with the risk of developing DILI, hepatotoxicity remains a mon side effect. 尽管在药物上市的过程中进行了广泛的安全性测试,但肝损伤仍然是神秘的,并且不能在临床前和临床试验中预测。不同的遗传变异体和生物标志物与肝损伤发展的风险相关,肝毒性仍然是非常常见的副作用。 1. Introduction In this review we will focus on the potential role of metabolomic study on the diagnosis and prognosis of DILI. 在这篇综述中,我们将重点关注代谢组学在肝损伤的诊断和预断中的潜在作用。 2. The Main Challenges in DILI: Accuracy of Diagnosis and Prediction of Evolution Currently, DILI is diagnosed by exclusion of other liver diseases and is frequently misdiagnosed. An important part in the diagnosis of DILI is to establish a temporal association between a drug and the onset of liver damage. However, in many cases, setting a causal link can be plex task as most of the idiosyncratic drug-induced reactions occur roughly between a range of 1-2 weeks and 2-3 months from the onset of drug administration 目前,肝损伤是通过排除其他肝病进行诊断的,而且经常被误诊。 DILI 诊断的一个重要部分是建立药物与肝损伤起始之间的时间关联。然而,在许多情况下,设置因果关联可以说是一件复杂的任务,因为大多数特异性药物诱导的反应大致在给药开始的 1-2 周和 2-3 个月的范围内才发生 2. The Main Challenges in DILI: Accuracy of Diagnosis and Prediction of